Molecular insights into mechanisms of the cell death program: Role in the progression of neurodegenerative disorders

Current Alzheimer Research

Volumn 3, Issue 4, 2006, Pages 269-283

  Culmsee, Carsten ^a   Landshamer, Stefan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

AIF; Alzheimer's disease; DNA damage; ER stress; GSK 3 ; Oxidative stress; Par 4; Protein phosphatases

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE; CELL NUCLEUS DNA; CYTOCHROME C; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR 4;

AGING; ALZHEIMER DISEASE; APOPTOSIS; BRAIN TISSUE; CALCIUM HOMEOSTASIS; CELL CYCLE; CELL DEATH; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DNA DAMAGE; ENDOPLASMIC RETICULUM; ENVIRONMENTAL FACTOR; HEREDITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; BRAIN; DISEASE PROGRESSION; DNA DAMAGE; HUMANS; MITOCHONDRIAL PROTEINS; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 33748473579     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506778249461     Document Type: Review

References (185)

1. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 430: 631-639 (2004).
2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766 (2001).
3. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739: 198-210 (2005).
4. Neve RL, McPhie DL, Chen Y. Alzheimer's disease: a dysfunction of the amyloid precursor protein. Brain Res886: 54-66 (2000).
5. Ho GJ, Drego R, Hakimian E, Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy 4: 247-256 (2005).
6. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1: 120-129 (2000).
7. Mattson MP, Duan W, Pedersen WA, Culmsee C. Cellular and molecular mechanisms underlying synaptic degeneration and neuronal death in Alzheimer's disease. In: Pathogenesis of Neurodegenerative Diseases (Ed: Mattson MP) Humana Press, Totowa, New Jersey, pp 113-138 (2001).
8. Selkoe DJ. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest 110: 1375-1381 (2002).
9. Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders - memantine, a new hope. Pharmacol Res 51: 1-17 (2005).
10. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24: 6144-6151 (2004).
11. Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol 75: 207-246 (2005).
12. Mattson MP. Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer's disease. J Neurovirol 8: 539-550 (2002).
13. Perry G, Nunomura A, Hirai K, Takeda A, Aliev G, Smith MA. Oxidative damage in Alzheimer's disease: the metabolic dimension. Int J Dev Neurosci 18: 417-421 (2000).
14. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19: 33-36 (1998).
15. Aksenov MY, Tucker HM, Nair P, Aksenova MV, Butterfield DA, Estus S, et al. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease J Mol Neurosci 11: 151-164 (1998) .
16. Keller JN, Mattson MP. Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev Neurosci 9: 105-116 (1998).
17. Murray IV, Sindoni ME, Axelsen PH. Promotion of oxidative lipid membrane damage by amyloid Beta proteins. Biochemistry 44: 12606-12613 (2005).
18. Kawahara M. Disruption of calcium homeostasis in the pathogenesis of Alzheimer's disease and other conformational diseases. Curr Alzheimer Res 1: 87-95 (2004).
19. Xiao J, Perry G, Troncoso J, Monteiro MJ. alpha-calcium-calmodulin- dependent kinase II is associated with paired helical filaments of Alzheimer's disease. J Neuropathol Exp Neurol 55: 954-963 (1996).
20. Grynspan F, Griffin WR, Cataldo A, Katayama S, Nixon RA. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res 763: 145-158 (1997).
21. Chan SL, Mattson MP. Caspase and calpain substrates: roles in synaptic plasticity and cell death. J Neurosci Res 58: 167-190 (1999).
22. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 83: 731-801 (2003).
23. Ray SK, Banik NL. Calpain and its involvement in the pathophysiology of CNS injuries and diseases: therapeutic potential of calpain inhibitors for prevention of neurodegeneration. Curr Drug Targets CNS Neurol Disord 2: 173-189 (2003).
24. Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 34: 385-397 (2003).
25. Sampson VL, Morrison JH, Vickers JC. The cellular basis for the relative resistance of parvalbumin and calretininimmunoreactive neocortical neurons to the pathology of Alzheimer's disease. Exp Neurol 145: 295-302 (1997).
26. Mattson MP, Gary DS, Chan SL, Duan W. Perturbed endoplasmic reticulum function, synaptic apoptosis and the pathogenesis of Alzheimer's disease. Biochem Soc Symp 67: 151-162 (2001).
27. Kelliher M, Fastbom J, Cowburn RF, Bonkale W, Ohm TG, Ravid R, et al. Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies. Neuroscience 92: 499-513 (1999).
28. Kurumatani T, Fastbom J, Bonkale WL, Bogdanovic N, Winblad B, Ohm TG, et al. Loss of inositol 1,4,5-trisphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology. Brain Res 796: 209-221 (1998).
29. Mattson MP, Guo Q. Cell and molecular neurobiology of presenilins: a role for the endoplasmic reticulum in the pathogenesis of Alzheimer's disease? J Neurosci Res 50: 505-513 (1997).
30. Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci 23: 222-229 (2000).
31. Dewachter I, Van Leuven F. Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol 1: 409-416 (2002).
32. Mattson MP. Neurobiology: Ballads of a protein quartet. Nature 422: 385-387 (2003).
33. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 4: 552-565 (2003).
34. Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 34: 325-337 (2003).
35. Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer's disease. Int J Neuropsychopharmacol 7: 351-369 (2004).
36. Nicotera P. Molecular switches deciding the death of injured neurons. Toxicol Sci 74: 4-9 (2003).
37. Bano D, Young KW, Guerin CJ, Lefeuvre R, Rothwell NJ, Naldini L, et al. Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell 120: 275-285 (2005) .
38. Schwab BL, Guerini D, Didszun C, Bano D, Ferrando-May E, Fava E, et al. Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis. Cell Death Differ 9: 818-831 (2002).
39. Lovell MA, Gabbita SP, Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 72: 771-776 (1999).
40. Chiarugi A. Poly(ADP-ribosyl)ation and stroke. Pharmacol Res 52: 15-24 (2005).
41. Culmsee C, Mattson MP. p53 in neuronal apoptosis. Biochem Biophys Res Commun 331: 761-777 (2005).
42. Kruman II, Wersto RP, Cardozo-Pelaez F, Smilenov L, Chan SL, Chrest FJ, et al. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 41: 549-561 (2004).
43. Love S, Barber R, Wilcock GK. Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain 122: 247-253 (1999).
44. Chiarugi A. Intrinsic Mechanisms of Poly(ADP-Ribose) Neurotoxicity: Three Hypotheses. Neurotoxicology 26: 847-855 (2005).
45. Adamczyk A, Czapski GA, Jesko H, Strosznajder RP. Non Abeta component of Alzheimer's disease amyloid and amyloid beta peptides evoked poly(ADP-ribose) polymerase-dependent release of apoptosis-inducing factor from rat brain mitochondria. J Physiol Pharmacol 2: 5-13 (2005)..
46. Dawson VL, Dawson TM. Deadly conversations: nuclear-mitochondrial cross-talk. J Bioenerg Biomembr 36: 287-294 (2004).
47. Chiarugi A, Moskowitz MA. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 85: 306-317 (2003) .
48. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 77: 220-228 (2001).
49. Strosznajder RP, Jesko H, Banasik M, Tanaka S. Effects of p53 inhibitor on survival and death of cells subjected to oxidative stress. J Physiol Pharmacol 56: 215-221 (2005).
50. Tamagno E, Parola M, Guglielmotto M, Santoro G, Bardini P, Marra L, et al. Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. Free Radic Biol Med 35: 45-58 (2003).
51. Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S, Camandola S, et al. Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J Neurosci 23: 8586-8595 (2003).
52. Leker RR, Aharonowiz M, Greig NH, Ovadia H. The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin alpha. Exp Neurol 187: 478-486 (2004).
53. Zhu X, Yu QS, Cutler RG, Culmsee CW, Holloway HW, Lahiri DK, et al. Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. J Med Chem 45: 5090-5097 (2002).
54. de la Monte S, Sohn YK, Wands JR. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 152: 73-83 (1997).
55. LaFerla FM, Hall CK, Ngo L, Jay G. Extracellular deposition of beta-amyloid upon p53-dependent neuronal cell death in transgenic mice. J Clin Invest 98: 1626-1632 (1996).
56. de la Monte SM. Molecular abnormalities of the brain in Down syndrome: relevance to Alzheimer's neurodegeneration, J Neural Transm Suppl 57: 1-19 (1999).
57. Chan SL, Culmsee C, Haughey N, Klapper W, Mattson MP. Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12. Neurobiol Dis 11: 2-19 (2002).
58. Keramaris E, Hirao A, Slack RS, Mak TW, Park DS. Ataxia telangiectasia-mutated protein can regulate p53 and neuronal death independent of Chk2 in response to DNA damage. J Biol Chem 278: 37782-37789 (2003).
59. Taylor W., Stark GR. Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815 (2001).
60. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 19: 175-178 (1998).
61. Chong MJ, Murray MR, Gosink EC, Russell HR, Srinivasan A, Kapsetaki M, et al. Atm and Bax cooperate in ionizing radiation-induced apoptosis in the central nervous system, Proc Natl Acad Sci USA 97: 889-894 (2000).
62. Macleod MR, Ramage L, McGregor A, Seckl JR. Reduced NMDA-induced apoptosis in neurons lacking ataxia telangiectasia mutated protein. Neuroreport 14: 215-217 (2003).
63. Kamer I, Sarig R, Zaltsman Y, Niv H, Oberkovitz G, Regev L, et al. Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 122: 593-603 (2005).
64. Zinkel SS, Hurov KE, Ong C, Abtahi FM, Gross A, Korsmeyer SJ. A role for proapoptotic BID in the DNA-damage response. Cell 122: 579-591 (2005).
65. Seth R, Yang C, Kaushal V, Shah SV, Kaushal GP. p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem 280: 31230-31239 (2005).
66. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 277: 13430-13437 (2002).
67. Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, Shelanski ML. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci 20: 1386-1392 (2000).
68. Herrup K, Neve R, Ackerman SL, Copani A. Divide and die: cell cycle events as triggers of nerve cell death. J Neurosci24: 9232-9239 (2004).
69. Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 18:2801-2807 (1998).
70. Alvarez A, Munoz JP, Maccioni RB. A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons. Exp Cell Res 264: 266-274 (2001).
71. Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS. Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F x DP, in B-amyloid-induced neuronal death. J Biol Chem 274: 19011-19016 (1999).
72. Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 336: 417-424 (1993).
73. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 276: 251-260 (2001).
74. Takashima A, Murayama M, Yasutake K, Takahashi H, Yokoyama M, Ishiguro K. Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci Lett 306: 37-40 (2001).
75. Flaherty DB, Soria JP, Tomasiewicz HG, Wood JG. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J Neurosci Res 62: 463-472 (2000).
76. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, et al. Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 88: 554-563 (2004).
77. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402: 615-622 (1999).
78. Town T, Zolton J, Shaffner R, Schnell B, Crescentini R, Wu Y, et al. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro . J Neurosci Res 69: 362-372 (2002).
79. Tseng HC, Zhou Y, Shen Y, Tsai LH. A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett 523: 58-62 (2002).
80. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57: 695-703 (2005).
81. Gibson GE, Sheu KF, Blass JP. Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Transm 105: 855-870 (1998).
82. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72: 609-642 (2003).
83. Plesnila N. Role of mitochondrial proteins for neuronal cell death after focal cerebral ischemia. Acta Neurochir Suppl 89: 15-19 (2004).
84. Polster BM, Fiskum G. Mitochondrial mechanisms of neural cell apoptosis. J Neurochem 90: 1281-1289 (2004).
85. Chan SL, Tammariello SP, Estus S, Mattson MP. Prostate apoptosis response-4 mediates trophic factor withdrawal-induced apoptosis of hippocampal neurons: actions prior to mitochondrial dysfunction and caspase activation. J Neurochem 73: 502-512 (1999).
86. Duan W, Rangnekar VM, Mattson MP. Prostate apoptosis response-4 production in synaptic compartments following apoptotic and excitotoxic insults: evidence for a pivotal role in mitochondrial dysfunction and neuronal degeneration. J Neurochem 72: 2312-2322 (1999).
87. Culmsee C, Zhu Y, Krieglstein J, Mattson MP. Evidence for the involvement of Par-4 in ischemic neuron cell death. J Cereb Blood Flow Metab 21: 334-343 (2001b).
88. Mattson MP, Duan W, Chan SL, Camandola S. Par-4: an emerging pivotal player in neuronal apoptosis and neurodegenerative disorders. J Mol Neurosci 13: 17-30 (1999).
89. Duan W, Zhang Z, Gash DM, Mattson MP. Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann Neurol 46: 587-597 (1999b).
90. Pedersen WA, Luo H, Kruman I, Kasarskis E, Mattson MP. The prostate apoptosis response-4 protein participates in motor neuron degeneration in amyotrophic lateral sclerosis. FASEB J 14: 913-924 (2000).
91. Guo Q, Fu W, Xie J, Luo H, Sells SF, Geddes JW, Bondada V, Rangnekar VM, Mattson MP. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat Med 4: 957-962 (1998).
92. Diaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L, et al. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86: 777-786 (1996).
93. Camandola S, Mattson MP. Pro-apoptotic action of PAR-4 involves inhibition of NF-kappaB activity and suppression of BCL-2 expression. J Neurosci Res 61: 134-139 (2000).
94. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 278: 19995-20005 (2003).
95. Sells SF, Han SS, Muthukkumar S, Maddiwar N, Johnstone R, Boghaert E, et al. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 17: 3823-3832 (1997).
96. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 16: 6945-6956 (1996).
97. Lovell MA, Xie C, Xiong S, Markesbery WR. Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. Brain Res 983: 84-96 (2003).
98. Rangnekar VM. Apoptosis mediated by a novel leucine zipper protein Par-4. Apoptosis 3: 61-66 (1998).
99. Lavrik I, Golks A, Krammer PH. Death receptor signaling. J Cell Sci 118: 265-267 (2005).
100. Boehrer S, Kukoc-Zivojnov N, Nowak D, Bergmann M, Baum C, Puccetti E, et al. Upon drug-induced apoptosis expression of prostate-apoptosis-response-gene-4 promotes cleavage of caspase-8, bid and mitochondrial release of cytochrome c. Hematology 9: 425-431 (2004).
101. El-Guendy N, Rangnekar VM. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res 283: 51-66 (2003).
102. Page G, Kogel D, Rangnekar V, Scheidtmann KH. Interaction partners of Dlk/ZIP kinase: co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis. Oncogene 18: 7265-7273 (1999).
103. Vetterkind S, Illenberger S, Kubicek J, Boosen M, Appel S, Naim HY, et al. Binding of Par-4 to the actin cytoskeleton is essential for Par-4/Dlk-mediated apoptosis. Exp Cell Res 305: 392-408 (2005).
104. Guo Q, Xie J. AATF inhibits aberrant production of amyloid beta peptide 1-42 by interacting directly with Par-4. J Biol Chem 279: 4596-4603 (2004).
105. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 333: 336-343 (2005).
106. Ward MW, Kogel D, Prehn JH. Neuronal apoptosis: BH3-only proteins the real killers? J Bioenerg Biomembr 36: 295-298 (2004).
107. Uo T, Kinoshita Y, Morrison RS. Neurons exclusively express N-Bak, a BH3 domain-only Bak isoform that promotes neuronal apoptosis. J Biol Chem 280: 9065-9073 (2005).
108. Paradis E, Douillard H, Koutroumanis M, Goodyer C, LeBlanc A. Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. J Neurosci 16: 7533-7539 (1996).
109. Selznick LA, Zheng TS, Flavell RA, Rakic P, Roth KA. Amyloid beta-induced neuronal death is bax-dependent but caspase-independent. J Neuropathol Exp Neurol 59: 271-279 (2000).
110. MacGibbon GA, Lawlor PA, Sirimanne ES, Walton MR, Connor B, Young D, et al. Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus. Brain Res 750: 223-234 (1997).
111. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, et al. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144: 891-901 (1999).
112. Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20: 929-935 (2000).
113. Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt R, Vogel J, et al. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 19: 3809-3817 (1999).
114. Plesnila N, Zinkel S, Le DA, Amin-Hanjani S, Wu Y, Qiu J, et al. BID mediates neuronal cell death after oxygen/ glucose deprivation and focal cerebral ischemia. Proc Natl Acad Sci USA 98: 15318-15323 (2001).
115. Becattini B, Sareth S, Zhai D, Crowell KJ, Leone M, Reed JC, et al. Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules. Chem Biol 11: 1107-1117 (2004).
116. Culmsee C, Zhu C, Stefan L, Becattini B, Wagner E, Pellechia M, et al. Apoptosis inducing factor triggered by PARP1 and Bid mediates neuronal cell death after oxygen/glucose deprivation and focal cerebral ischemia. J Neuroscience 25: 10262-10272 (2005)
117. Becker EB, Howell J, Kodama Y, Barker PA, Bonni A. Characterization of the c-Jun N-terminal kinase-BimEL signaling pathway in neuronal apoptosis. J Neurosci 24: 8762-8770 (2004).
118. Liu X, Dai S, Zhu Y, Marrack P, Kappler JW. The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity 19: 341-352 (2003).
119. Wilson-Annan J, O'Reilly LA, Crawford SA, Hausmann G, Beaumont JG, Parma LP, et al. Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. J Cell Biol 162: 877-887 (2003).
120. Okazawa H, Estus S. The JNK/c-Jun cascade and Alzheimer's disease. Am J Alzheimers Dis Other Demen 17: 79-88 (2002).
121. Yao M, Nguyen TV, Pike CJ. Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. J Neurosci 25: 1149-1158 (2005) .
122. Zhu X, Wang Y, Ogawa O, Lee HG, Raina AK, Siedlak SL, et al. Neuroprotective properties of Bcl-w in Alzheimer disease. J Neurochem 89: 1233-1240 (2004).
123. Saille C, Marin P, Martinou JC, Nicole A, London J, Ceballos-Picot I. Transgenic murine cortical neurons expressing human Bcl-2 exhibit increased resistance to amyloid beta-peptide neurotoxicity. Neuroscience 92: 1455-1463 (1999).
124. Song YS, Park HJ, Kim SY, Lee SH, Yoo HS, Lee HS, et al. Protective role of Bcl-2 on beta-amyloid-induced cell death of differentiated PC12 cells: reduction of NF-kappaB and p38 MAP kinase activation. Neurosci Res 49: 69-80 (2004).
125. Tan J, Town T, Placzek A, Kundtz A, Yu H, Mullan M. Bcl-X(L) inhibits apoptosis and necrosis produced by Alzheimer's beta-amyloid1-40 peptide in PC12 cells. Neurosci Lett 272: 5-8 (1999).
126. Jordan J, Cena V, Prehn JH. Mitochondrial control of neuron death and its role in neurodegenerative disorders. J Physiol Biochem 59: 129-141 (2003).
127. Stefanis L. Caspase-dependent and -independent neuronal death: two distinct pathways to neuronal injury. Neuroscientist 11: 50-62 (2005).
128. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature 407: 802-809 (2000).
129. Allen JW, Eldadah BA, Huang X, Knoblach SM, Faden AI. Multiple caspases are involved in beta-amyloid-induced neuronal apoptosis. J Neurosci Res 65: 45-53 (2001).
130. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97: 395-406 (1999).
131. Le DA, Wu Y, Huang Z, Matsushita K, Plesnila N, Augustinack JC, et al. Caspase activation and neuroprotection in caspase-3- deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc Natl Acad Sci USA 99:15188-15193 (2002).
132. Rideout HJ, Stefanis L. Caspase inhibition: a potential therapeutic strategy in neurological diseases. Histol Histopathol 16:895-908 (2001).
133. Bilsland J, Harper S. Caspases and neuroprotection. Curr Opin Investig Drugs 3: 1745-1752 (2002).
134. McLaughlin B. The kinder side of killer proteases: caspase activation contributes to neuroprotection and CNS remodeling. Apoptosis 9: 111-121 (2004) .
135. Gillardon F, Kiprianova I, Sandkuhler J, Hossmann KA, Spranger M. Inhibition of caspases prevents cell death of hippocampal CA1 neurons, but not impairment of hippocampal long-term potentiation following global ischemia. Neuroscience 93: 1219-1222 (1999).
136. Ferrer I, Friguls B, Dalfo E, Justicia C, Planas AM. Caspase-dependent and caspase-independent signalling of apoptosis in the penumbra following middle cerebral artery occlusion in the adult rat. Neuropathol Appl Neurobiol 29: 472-481 (2003).
137. Volbracht C, Leist M, Kolb SA, Nicotera P. Apoptosis in caspase-inhibited neurons. Mol Med 7: 36-48 (2001).
138. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 23: 2785-2796 (2004).
139. Plesnila N, Zhu C, Culmsee C, Groger M, Moskowitz MA, Blomgren K. Nuclear translocation of apoptosis-inducing factor after focal cerebral ischemia. J Cereb Blood Flow Metab 24: 458-466 (2004).
140. Cheung EC, Melanson-Drapeau L, Cregan SP, Vanderluit JL, Ferguson KL, McIntosh WC, et al. Apoptosis-inducing factor is a key factor in neuronal cell death propagated by BAX-dependent and BAX-independent mechanisms. J Neurosci 25: 1324-1334 (2005).
141. Zhang X, Chen J, Graham SH, Du L, Kochanek PM, Draviam R, et al. Intranuclear localization of apoptosis-inducing factor (AIF) and large scale DNA fragmentation after traumatic brain injury in rats and in neuronal cultures exposed to peroxynitrite.J Neurochem 82: 181-191 (2002).
142. Liou AK, Zhou Z, Pei W, Lim TM, Yin XM, Chen J. BimEL upregulation potentiates AIF translocation and cell death in response to MPTP. FASEB J 19: 1350-1352 (2005).
143. Polster BM, Basanez G, Etxebarria A, Hardwick JM, Nicholls DG. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem 280: 6447-6454 (2005).
144. Paschen W, Frandsen A. Endoplasmic reticulum dysfunction - a common denominator for cell injury in acute and degenerative diseases of the brain? J Neurochem 79: 719-725 (2001).
145. DeGracia DJ, Montie HL. Cerebral ischemia and the unfolded protein response. J Neurochem 91: 1-8 (2004).
146. Katayama T, Imaizumi K, Manabe T, Hitomi J, Kudo T, Tohyama M. Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat 28: 67-78 (2004).
147. Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29: 15-32 (2001).
148. Guo Q, Sopher BL, Furukawa K, Pham DG, Robinson N, Martin GM, et al. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. J Neurosci 17: 4212-4222 (1997).
149. Katayama T, Imaizumi K, Sato N, Miyoshi K, Kudo T, Hitomi J, et al. Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Biol 1: 479-485 (1999).
150. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403: 98-103 (2000).
151. Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, Koyama Y, et al. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. J Cell Biol 165: 347-356 (2004).
152. Reimertz C, Kogel D, Rami A, Chittenden T, Prehn JH. Gene expression during ER stress-induced apoptosis in neurons: induction of the BH3-only protein Bbc3/PUMA and activation of the mitochondrial apoptosis pathway. J Cell Biol 162: 587-597 (2003).
153. Mattson MP, Chan SL. Calcium orchestrates apoptosis. Nat Cell Biol 5: 1041-1043 (2003).
154. Boehning D, van Rossum DB, Patterson RL, Snyder SH. A peptide inhibitor of cytochrome c/inositol 1,4,5-trisphosphate receptor binding blocks intrinsic and extrinsic cell death pathways. Proc Natl Acad Sci U S A. 102: 1466-1471 (2005).
155. Boehning D, van Rossum DB, Patterson RL, Snyder SH. A peptide inhibitor of cytochrome c/inositol 1,4,5-trisphosphate receptor binding blocks intrinsic and extrinsic cell death pathways. Proc Natl Acad Sci U S A. 102: 1466-1471 (2005).
156. Filippin L, Magalhaes PJ, Di Benedetto G, Colella M, Pozzan T. Stable interactions between mitochondria and endoplasmic reticulum allow rapid accumulation of calcium in a subpopulation of mitochondria. J Biol Chem 278: 39224-39234 (2003).
157. Simmen T, Aslan JE, Blagoveshchenskaya AD, Thomas L, Wan L, Xiang Y, et al. PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. EMBO J 24: 717-729 (2005).
158. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and - independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11: 297-305 (2001).
159. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 1-16 (2001).
160. Shaw M, Cohen P, Alessi DR. Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett 416: 307-311 (1997).
161. Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW, Lee CM. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci USA. 97: 11074-11079 (2000).
162. Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 297: 186-196 (2004).
163. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2: 3-18 (2005).
164. Kim HS, Kim EM, Lee JP, Park CH, Kim S, Seo JH, et al. C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. FASEB J. 17: 1951-1953 (2003).
165. Koh SH, Kim SH, Kwon H, Park Y, Kim KS, Song CW, et al. Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res Mol Brain Res 118: 72-81 (2003).
166. Crowder RJ, Freeman RS. Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J Biol Chem 275: 34266-34271 (2000).
167. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89: 1313-1317 (2004).
168. Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 25: 471-480 (2004).
169. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56: 70-78 (1997).
170. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, et al. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 31: 317-323 (1998).
171. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 453: 260-264 (1999).
172. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20: 27-39 (2001).
173. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci USA 90: 7789-7793 (1993).
174. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439 (2003).
175. Terwel D, Dewachter I, Van Leuven F. Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. Neuromolecular Med 2: 151-165 (2002).
176. Chen Q, Yoshida H, Schubert D, Maher P, Mallory M, Masliah E. Presenilin binding protein is associated with neurofibrillary alterations in Alzheimer's disease and stimulates tau phosphorylation. Am J Pathol 159: 1597-1602 (2001) .
177. Lee W, Boo JH, Jung MW, Park SD, Kim YH, Kim SU, et al. Amyloid beta peptide directly inhibits PKC activation. Mol Cell Neurosci 26: 222-231 (2004).
178. Cardoso SM, Oliveira CR. The role of calcineurin in amyloid-beta- peptides-mediated cell death. Brain Res 1050: 1-7 (2005).
179. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 16: 395-419 (1998).
180. Zhu Y, Schwarz S, Ahlemeyer B, Grzeschik S, Klumpp S, Krieglstein J. Oleic acid causes apoptosis and dephosphorylates Bad. Neurochem Int 46: 127-135 (2005).
181. Pei JJ, Gong CX, An WL, Winblad B, Cowburn RF, Grundke-Iqbal I, et al. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol 163: 845-858 (2003).
182. Huang HM, Fowler C, Xu H, Zhang H, Gibson GE. Mitochondrial function in fibroblasts with aging in culture and/or Alzheimer's disease. Neurobiol Aging 26: 839-848 (2005).
183. Miller FD, Kaplan DR. Neurotrophin signalling pathways regulating neuronal apoptosis. Cell Mol Life Sci 58: 1045-1053 (2001).
184. Gerling N, Culmsee C, Klumpp S, Krieglstein J. The tyrosine phosphatase inhibitor orthovanadate mimics NGF-induced neuroprotective signaling in rat hippocampal neurons. Neurochem Int 44: 505-520 (2004).
185. Barrett DM, Black SM, Todor H, Schmidt-Ullrich RK, Dawson KS, Mikkelsen RB. Inhibition of protein-tyrosine phosphatases by mild oxidative stresses is dependent on S-nitrosylation. J Biol Chem 280: 14453-14461 (2005).